-
Something wrong with this record ?
Interaction of a Potential Anticancer Agent Hypericin and its Model Compound Emodin with DNA and Bovine Serum Albumin
J. Staničová, V. Verebová, J. Beneš,
Language English Country Greece
Document type Journal Article
NLK
Free Medical Journals
from 2004 to 2 years ago
PubMed Central
from 2017
Europe PubMed Central
from 2017
Open Access Digital Library
from 2004-01-01
PubMed
30150427
DOI
10.21873/invivo.11347
Knihovny.cz E-resources
- MeSH
- DNA chemistry metabolism MeSH
- Emodin chemistry pharmacology MeSH
- Molecular Structure MeSH
- Perylene analogs & derivatives chemistry pharmacology MeSH
- Antineoplastic Agents chemistry pharmacology MeSH
- Serum Albumin, Bovine chemistry metabolism MeSH
- Spectrum Analysis MeSH
- Thermodynamics MeSH
- Protein Binding MeSH
- Structure-Activity Relationship MeSH
- Animals MeSH
- Check Tag
- Animals MeSH
- Publication type
- Journal Article MeSH
BACKGROUND/AIM: We report the incorporation of prospective anticancer agent hypericin into DNA and bovine serum albumin (BSA), respectively, with emphasis on comparison of the differences in interaction mode between hypericin and its model compound emodin. MATERIALS AND METHODS: Spectrophotometric methods were used for determination of the binding constants of the drug complex with biomacromolecules. Differential scanning calorimetry was applied for evaluation of drug-macromolecule complex thermal stability. RESULTS: The strength of interaction expressed by binding constants was found to be 4.0×104 l/mol for hypericin-DNA and 8.1×104 l/mol for emodin-DNA complex. Both molecules stabilize bovine serum albumin macromolecule and bind into the hydrophobic cavity in IIA subunit but their localization within the molecule is different. CONCLUSION: Anticancer agent hypericin and its derivative emodin interact with DNA with medium strength and are probably incorporated into the groove of DNA by hydrogen bonds. Bovine serum albumin can serve as a transport protein for hypericin since the binding force between both molecules is adequate.
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc19000417
- 003
- CZ-PrNML
- 005
- 20211223100751.0
- 007
- ta
- 008
- 190107s2018 gr f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.21873/invivo.11347 $2 doi
- 035 __
- $a (PubMed)30150427
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a gr
- 100 1_
- $a Staničová, Jana, $u Institute of Biophysics, University of Veterinary Medicine & Pharmacy, Košice, Slovakia jana.stanicova@uvlf.sk. Institute of Biophysics & Informatics, First Faculty of Medicine, Charles University, Prague, Czech Republic. $d 1960- $7 xx0267735
- 245 10
- $a Interaction of a Potential Anticancer Agent Hypericin and its Model Compound Emodin with DNA and Bovine Serum Albumin / $c J. Staničová, V. Verebová, J. Beneš,
- 520 9_
- $a BACKGROUND/AIM: We report the incorporation of prospective anticancer agent hypericin into DNA and bovine serum albumin (BSA), respectively, with emphasis on comparison of the differences in interaction mode between hypericin and its model compound emodin. MATERIALS AND METHODS: Spectrophotometric methods were used for determination of the binding constants of the drug complex with biomacromolecules. Differential scanning calorimetry was applied for evaluation of drug-macromolecule complex thermal stability. RESULTS: The strength of interaction expressed by binding constants was found to be 4.0×104 l/mol for hypericin-DNA and 8.1×104 l/mol for emodin-DNA complex. Both molecules stabilize bovine serum albumin macromolecule and bind into the hydrophobic cavity in IIA subunit but their localization within the molecule is different. CONCLUSION: Anticancer agent hypericin and its derivative emodin interact with DNA with medium strength and are probably incorporated into the groove of DNA by hydrogen bonds. Bovine serum albumin can serve as a transport protein for hypericin since the binding force between both molecules is adequate.
- 650 _2
- $a zvířata $7 D000818
- 650 _2
- $a protinádorové látky $x chemie $x farmakologie $7 D000970
- 650 _2
- $a DNA $x chemie $x metabolismus $7 D004247
- 650 _2
- $a emodin $x chemie $x farmakologie $7 D004642
- 650 _2
- $a molekulární struktura $7 D015394
- 650 _2
- $a perylen $x analogy a deriváty $x chemie $x farmakologie $7 D010569
- 650 _2
- $a vazba proteinů $7 D011485
- 650 _2
- $a sérový albumin hovězí $x chemie $x metabolismus $7 D012710
- 650 _2
- $a spektrální analýza $7 D013057
- 650 _2
- $a vztahy mezi strukturou a aktivitou $7 D013329
- 650 _2
- $a termodynamika $7 D013816
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Verebová, Valéria $u Institute of Biophysics, University of Veterinary Medicine & Pharmacy, Košice, Slovakia. $7 xx0267732
- 700 1_
- $a Beneš, Jiří $u Institute of Biophysics & Informatics, First Faculty of Medicine, Charles University, Prague, Czech Republic.
- 773 0_
- $w MED00175831 $t In vivo (Athens, Greece) $x 1791-7549 $g Roč. 32, č. 5 (2018), s. 1063-1070
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/30150427 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20190107 $b ABA008
- 991 __
- $a 20211223100748 $b ABA008
- 999 __
- $a ok $b bmc $g 1364503 $s 1038540
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2018 $b 32 $c 5 $d 1063-1070 $i 1791-7549 $m In Vivo $n In Vivo $x MED00175831
- LZP __
- $a Pubmed-20190107
